These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36343291)

  • 21. Effect of early adjunctive use of oral sildenafil and inhaled nitric oxide on the outcome of pulmonary hypertension in newborn infants. A feasibility study.
    Al Omar S; Salama H; Al Hail M; Al Rifai H; Bunahia M; El Kasem W; Siddiqui FJ; Dilawar M; Yassin H; Masud F; Mohamed A; Mansour A
    J Neonatal Perinatal Med; 2016 Sep; 9(3):251-9. PubMed ID: 27589542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Efficacy and Safety of Different Doses of Sildenafil in the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Network Meta-analysis.
    Sun L; Wang C; Zhou Y; Sun W; Wang C
    Front Pharmacol; 2021; 12():697287. PubMed ID: 34630080
    [No Abstract]   [Full Text] [Related]  

  • 23. Outcome of oral sildenafil in neonatal persistent pulmonary hypertension of non-cardiac causes.
    Sayed A; Bisheer N
    J Neonatal Perinatal Med; 2015; 8(3):215-20. PubMed ID: 26485555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
    Grünig E; Ohnesorge J; Benjamin N; Burhenne J; Enderle Y; Egenlauf B; Fischer C; Harutyunova S; Huppertz A; Klose H; Haefeli WE
    Respiration; 2017; 94(1):26-37. PubMed ID: 28494463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis.
    Fu W; He W; Li Y; Chen Y; Liang J; Lei H; Fu L; Chen Y; Ren N; Jiang Q; Shen Y; Ma R; Wang T; Wang X; Zhang N; Xiao D; Liu C
    Drug Deliv; 2021 Dec; 28(1):1007-1019. PubMed ID: 34060401
    [No Abstract]   [Full Text] [Related]  

  • 26. Systematic review and cost-effectiveness of bosentan and sildenafil as therapeutic drugs for pediatric pulmonary arterial hypertension.
    Chen T; Chen J; Chen C; Zheng H; Chen Y; Liu M; Zheng B
    Pediatr Pulmonol; 2021 Jul; 56(7):2250-2258. PubMed ID: 33856119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats.
    Clozel M; Hess P; Rey M; Iglarz M; Binkert C; Qiu C
    Exp Biol Med (Maywood); 2006 Jun; 231(6):967-73. PubMed ID: 16741032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome of oral sildenafil therapy on persistent pulmonary hypertension of the newborn at Queen Sirikit National Institute of Child Health.
    Khorana M; Yookaseam T; Layangool T; Kanjanapattanakul W; Paradeevisut H
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S64-73. PubMed ID: 22043756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States.
    Angalakuditi M; Edgell E; Beardsworth A; Buysman E; Bancroft T
    J Med Econ; 2010; 13(3):393-402. PubMed ID: 20608882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment with sildenafil, bosentan, or both in children and young people with idiopathic pulmonary arterial hypertension and Eisenmenger's syndrome].
    Raposo-Sonnenfeld I; Otero-González I; Blanco-Aparicio M; Ferrer-Barba A; Medrano-López C
    Rev Esp Cardiol; 2007 Apr; 60(4):366-72. PubMed ID: 17521545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute effect of sildenafil is maintained in pulmonary arterial hypertension patients chronically treated with bosentan.
    Hatano M; Yao A; Kinugawa K; Hirata Y; Nagai R
    Int Heart J; 2011; 52(4):233-9. PubMed ID: 21828950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endothelin-1 decreases endothelial PPARγ signaling and impairs angiogenesis after chronic intrauterine pulmonary hypertension.
    Wolf D; Tseng N; Seedorf G; Roe G; Abman SH; Gien J
    Am J Physiol Lung Cell Mol Physiol; 2014 Feb; 306(4):L361-71. PubMed ID: 24337925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sildenafil for pulmonary hypertension in neonates.
    Shah PS; Ohlsson A
    Cochrane Database Syst Rev; 2007 Jul; (3):CD005494. PubMed ID: 17636802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
    Vizza CD; Jansa P; Teal S; Dombi T; Zhou D
    BMC Cardiovasc Disord; 2017 Sep; 17(1):239. PubMed ID: 28874133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn.
    Mohamed WA; Ismail M
    J Perinatol; 2012 Aug; 32(8):608-13. PubMed ID: 22076415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistent pulmonary hypertension in the newborn: therapeutic effect of sildenafil.
    Cruz-Blanquel A; Espinosa-Oropeza A; Romo-Hernández G; Carrillo-Alarcón L; Ponce-Monter H; Ortiz MI
    Proc West Pharmacol Soc; 2008; 51():73-7. PubMed ID: 19544683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre.
    Douwes JM; Roofthooft MT; Van Loon RL; Ploegstra MJ; Bartelds B; Hillege HL; Berger RM
    Heart; 2014 Feb; 100(3):224-30. PubMed ID: 24390161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bosentan in the treatment of persistent pulmonary hypertension in newborns: a systematic review and meta-analysis.
    Gao N; Lv Y; Cui Y; Wang P; He X
    Cardiol Young; 2024 Feb; ():1-8. PubMed ID: 38329072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral Sildenafil Use In Neonates With Persistent Pulmonary Hypertension Of Newborn.
    Hussain AS; Ali R; Ahmed S; Naz F; Haroon A
    J Ayub Med Coll Abbottabad; 2017; 29(4):677-680. PubMed ID: 29331003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network meta-analysis.
    Cao F; Wu K; Zhu YZ; Jiang JJ; Zhang G; Liu J; Xiao P; Tian Y; Zhang W; Zhang S; Hou F; Bao ZW
    Front Cardiovasc Med; 2022; 9():1055897. PubMed ID: 36712266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.